News

“Virades de l’espoir” 2022: Walks of hope in France to help in the fight against cystic fibrosis

Les Virades de l'espoir 2022

September 23, 2022

2002-2022: 20 years of major progress

The year 2022 marks 20 years of major advances in the diagnosis and management of cystic fibrosis in France and around the world:

These measures have made it possible to improve the prognosis of this disease, allowing early diagnosis and multidisciplinary management organized within the CRCMs from the first weeks of life thanks to neonatal screening. The benefits for patients have been observed at all levels of care, with a favorable cost-benefit ratio:

  • improved respiratory and nutritional prognoses
  • increased survival
  • reduction in the burden of treatments.

Further progress is needed

Despite these important advances, many patients are still missing out on innovative treatments. In addition, there are currently no curative treatments for patients with cystic fibrosis. Thus, further efforts are needed to continue to combat this disease.

“Virades de l’espoir”: Walks of Hope to raise awareness and funds

The “Virades de l’espoir”, created in 1985, help raise awareness of the fight against cystic fibrosis and raise funds to improve the lives of patients with the disease, most notably by funding research into the development of new treatments.

World Alzheimer’s Day 2022

Sketchnote les 5 systèmes de mémoire

September 21, 2022

Alzheimer’s disease is a major global healthcare challenge. The number of people living with Alzheimer’s disease or other forms of dementia is currently estimated at over 55 million worldwide, and this number is expected to reach 78 million by 2030. The prevalence of dementia is estimated at around 10 million across all European countries, and is expected to almost double by 2050. In France, 2.2 million people may be affected by the disease by 2050.

This year, World Alzheimer’s Day is on September 21, 2022. As part of the theme, “Know dementia, Know Alzheimer’s”, we invite you to take another look at the impact of this neurodegenerative disease on the different types of memory: not all types of memory are affected in the same way by the disease, and some memories are relatively well preserved.

Impact of Alzheimer’s disease on the different types of memory

  • The most notable first signs of memory problems in Alzheimer’s disease concern episodic memory, which is involved in the recall of personal events. People with this type of memory deficit often struggle to remember what they did the day before, or recent significant events.
  • Deficits in semantic memory, which result in problems remembering general information, are perhaps less noticeable than other types of memory loss but probably appear at the same time, or even before other memory problems. This type of memory deficit can result in individuals finding it increasing difficult to find words, and recall the names of people, objects and places.
  • Alzheimer’s disease also leads to working memory disorders, which makes it difficult to retain short-term information, such as telephone numbers.
  • On the other hand, procedural memory, which is involved in the performance of gestures and skills that do not require direct conscious awareness, such as knowing how to play the piano or ride a bike, remains preserved for a relatively long time during the disease course.
  • Finally, sensory memory is the form of memory that best resists Alzheimer’s disease and can be used in sensory stimulation workshops.

The expertise of Santé Active Edition – Synergy Pharm

You may also be interested in other projects we have carried out on this theme for the “Observatoire des mémoires du Groupe B2V”:

To learn more:

Further information about the types of memory affected in Alzheimer’s disease can be found at:

For information on the disease, its impact on daily life, and the latest World Alzheimer Report, you can download the open-access resources available from websites of Alzheimer’s Disease International and the Vaincre Alzheimer Foundation:

Information about ongoing research projects and recent research advances can be found on the websites of Alzheimer Europe and the Fondation Recherche Alzheimer:

World Patient Safety Day 2022

Medication Without Harm - Global Patient Safety Challenge

September 13, 2022

Synergy Pharm keeps you informed about medication safety, the theme chosen by the World Health Organization (WHO) for the 2022 edition of World Patient Safety Day.

Regulatory documents for drug safety:

Several regulatory documents are required to ensure the safety of a drug before it is made available on the market.

  • One of the first key steps is the drug benefit/risk assessment included in the CTD (Common Technical Document) submitted to the health authorities.
  • Additional specific documents may be requested at the time of submission, such as the “120-day safety update” and the DALA (Drug Abuse Liability Assessment) for the Food and Drug Administration (FDA) in the United States.
  • Once the product is available on the market, various pharmacovigilance systems are set up to allow the safety of the product to be monitored during its use by patients. Several safety reports are thus issued during the drug development phase (DSURs) and are periodically updated (PSURs/PBRERs).

Raising patient awareness on medication safety:

Ensuring the safe use of medication is essential for reducing patient harm. Especially since the COVID-19 pandemic has significantly exacerbated the risk of medication errors and associated medication-related harm. There are several interventions that can help to limit the frequency and impact of medication errors.

  • Starting a medication
  • Taking a medication
  • Adding a medication
  • Reviewing medication
  • Stopping medication

New supplement dedicated to skin cancer

From photoprotection to dermato-oncology

July 21, 2022

Read more

Implementation of the IVDR: Regulation (EU) 2017/746 for in vitro diagnostic medical devices

Regulation (EU) 2017/746 will come into force for in vitro diagnostic medical devices (IVDMDs) on May26, 2022

May 19, 2022

Help is on hand to guide companies through the transition

The expertise of Santé Active Edition – Synergy Pharm

We can also support you in writing the scientific article relating to your clinical investigation.  

Recent examples of articles about IVDMDs written by our team include:

Do not hesitate to contact us to discuss your projects!

European Patients’ Rights Day

European Charter of Patients' Rights

April 18, 2022

April 18 is European Patients’ Rights Day (EPRD).

More specifically, this charter proclaims:

  • The right to information (“access to all that scientific research and technological innovation makes available”),
  • The right to consent for any procedure or treatment, but also for participation in clinical trials,
  • The right to innovation (“right of access to innovative procedures, including diagnostic procedures”), which implies the right of access to treatments or medical devices assessed in clinical trials.

The European Clinical Trials Regulation (Regulation (EU) No 536/2014) also aims to guarantee the rights of patients, and all of the medical writers at Synergy Pharm/Santé Active Edition are committed to ensuring that information relating to compliance with ethical standards and good clinical practice is clearly stated in publications reporting the results of clinical trials.

French “Week Against Cancer” 2022

Xerosis anticancer treatments

March 14, 2022

On the occasion of the national “Week Against Cancer” campaign in France, it is important to highlight research efforts aimed at reducing the side effects associated with cancer treatments.

Indeed, while the range of treatments available – used alone or in combination – are effective against cancer, they can have many side effects, particularly on the skin. Xerosis is one of the most frequent side effects of cancer therapy and requires appropriate management to help maintain patient quality of life and prevent potential interruptions to cancer treatment.

A recent multicenter, real-world, phase IV study demonstrated the benefits of using an emollient containing a postbiotic in the management of 319 patients with xerosis associated with a range of cancer treatments (chemotherapy, targeted therapy, radiotherapy, hormonotherapy and immunotherapy).

A previous multicentre, real-world, phase IV study had already demonstrated the effectiveness of this emollient for the management of xerosis in 5,910 patients with a range of skin conditions (atopic dermatitis, senile xerosis, ichthyosis, psoriasis, prurigo nodularis of Hyde etc.) and underlying systemic conditions (diabetes mellitus, thyroid disease, renal insufficiency, etc.).

These two articles, published in Dermatology and Therapy and written by our medical writing team, can be found here:

Brain Awareness Week 2022

Brain Awareness Week

March 9, 2022

*Learning, Brain and Artificial Intelligence, Brain and New Technologies, Brain and Society, Brain and Sport, Sleep, The 5 senses, Emotions, Memory, The Sick Brain.

World Rare Disease Day 2022

February 28, 2022

By definition, a rare disease has a prevalence of 1/2,000. But rare diseases are numerous and would affect more than 3 million people in France, more than 300 million in the world!

Most of these diseases have no treatment. Nevertheless, many actors are mobilized in the fight against rare diseases to improve the diagnosis, care and follow-up of the patients concerned; research in this area also allows significant medical advances.

In 2021, we again had the opportunity to put our medical writing skills at the service of several rare diseases, including craniofacial microsomia, cystic fibrosis, and inherited epidermolysis bullosa.

Read more

World Neglected Tropical Disease Day 2022

World NTD Day 2022

January 25, 2022

Read more